Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03591614	Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma	withdrawn	Early Phase 1	0	Case Comprehensive Cancer CenterOTHER	1	Aug 18, 2023	clinicaltrials
NCT01571726	Imaging Studies and the Development of Multiple Myeloma	withdrawn	Phase 2	0	National Cancer Institute (NCI)NIH	0	Dec 16, 2019	clinicaltrials